CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target
CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target
This is a trial to determine if patients who are well controlled and on basal insulin are
 treated with excessive basal dose.
In many clinical trials, basal insulin is titrated to only a fasting glucose goal. The usual
 final dose is >0.4U/kg. In carefully CGM monitored/titrated studies in both basal insulin
 alone or in pump-treated T2DM, we have found the basal insulin dose to be <0.3U/kg. This
 suggests that if guided by a single daily fasting glucose, titration may result in an
 excessive basal dose. This study will examine that issue.
Inclusion Criteria:

 -  Type 2 diabetes

 -  Age 18 years and above

 -  Concurrently on +/-thiazolidnedione +/-DDP IV inhibitors +/-metformin +/- glinides and
 basal insulin analogs

 -  A1C 10% or below

 -  Capable of self monitoring glucose at least 4 x a day

 -  Previously compliant with clinical recommendations

 -  Fasting blood glucose <110mg/dl average for 3 consecutive days

 -  BMI <45 kg/m

 Exclusion Criteria:

 -  Urinary ketosis

 -  Current or expected alternation in insulin sensitivity such as major surgery,
 infection, renal failure, glucocorticoid treatment, recent serious hypoglycaemic
 episode

 -  Currently participating in another clinical trial

 -  Using rapid insulin insulin

 -  Pregnancy or nursing or the intention of becoming pregnant or not using adequate birth
 control

 -  Significant liver or heart failure.